FindTrial
Sign In

The median effective doses of Remimazolam Tosilate combined with different doses of fentanyl in elder patients for painless gastroscopy

Quantitative relationship study of fentanyl compounded with remazolam in painless gastroscopy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077778
Enrollment
Unknown
Registered
2023-11-20
Start date
2023-11-20
Completion date
Unknown
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroscopy

Interventions

F1 group:Fentanyl 0.5ug/kg
F2 group:Fentanyl 1.0ug/kg
F3 group:Fentanyl 1.5ug/kg

Sponsors

Affiliated Hospital of North Sichuan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients selected for elective painless gastroscopy, ASA classification ?-?, age ? 65 years, BMI 18-30 kg /m2

Exclusion criteria

Exclusion criteria: Refusal to sign informed consent for the trial, history of sedative drug abuse, history of opioid and benzodiazepine allergy, uncontrolled severe hypertension, unstable angina pectoris, presence of apnea sleep syndrome, severe respiratory disease .

Design outcomes

Primary

MeasureTime frame
median effective dose of Remazolam;—

Secondary

MeasureTime frame
Remazolam 95% effective dose;Check operation time, patient wake time, recovery room retention time;Patient vital signs at corresponding time points(SBP,DBP,MAP, HR, SPO2);Perioperative side effects (hypotension, hypoxia, injection pain, diaphragm convulsions, postoperative nausea and vomiting, etc.);—

Countries

china

Contacts

Public ContactGuo Yanxia

Affiliated Hospital of North Sichuan Medical College

1240044860@qq.com+86 136 9829 9579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026